FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1730502540> ?p ?o ?g. }

• W1730502540 endingPage "11016" @default.
• W1730502540 startingPage "11016" @default.
• W1730502540 abstract "11016 Background: Induction of apoptosis is a common effect of many new and existing drugs, and Bcl-2 expression is associated with resistance to apoptosis. CTCs are a minimally invasive blood test and are a source of tumor cells that can be obtained serially during therapy. Monitoring Bcl-2, apoptosis, and other markers in CTCs may be useful endpoints in trials of new and targeted agents. The goal of this pilot study is to estimate Bcl-2 expression and apoptosis in CTCs from pts being treated for metastatic breast cancer (MBC). Methods: Whole blood was collected from pts initiating therapy for MBC at baseline, post-treatment (24, 48, or 72 hours), and 3–4 weeks. Samples were split into 3 × 7.5ml fractions. CTCs were isolated and enumerated using the CellTracks and CellSpotter systems. CTCs were defined as DAPI+, cytokeratin+, CD45-, with a cellular morphology. Apoptosis defined by positive staining with MAb M30. Bcl-2 status defined by staining with MAb Bcl-2–100. Results: 39/81 patients (49%) had ≥5 CTCs at baseline. 25% had ≥5 CTCs at 3–4 weeks. 35% of pts with CTCs had positive Bcl-2 staining in 91–100% of their CTCs (highest decile). Other pts were equally distributed across the remaining Bcl-2 deciles. At baseline, apoptosis correlates with CTC number. In samples with 1–4 CTCs, 80% of cells were apoptotic. For 5–49 CTCs, 48% were apoptotic; for 50–99, 34% were apoptotic; for 100–500, 28% were apoptotic; and for >500, 22% were apoptotic. Bcl-2 staining was inversely correlated with apoptosis staining. Pts were risk stratified by changes in CTC number after one cycle of therapy, and apoptosis increased with improving prognostic groups. One pt had markedly elevated CTCs of >20,000. The cells were remarkably 100% Bcl-2 positive and M30 negative (1% staining). Conclusions: These data confirm the prevalence of CTCs seen in the pivotal trial of CTCs in MBC (Cristofanilli NEJM 2004) and provide novel observations for Bcl-2 expression and apoptosis in CTCs. Higher Bcl-2 expression appears to correlate with decreased apoptosis. High fractions of apoptotic cells correlate with lower numbers of CTCs, which is associated with a better prognosis. Analysis of the post-treatment (24, 48, or 72 hour) samples and correlation of markers with progression free survival are ongoing and will be presented. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Immunicon Immunicon Immunicon Immunicon" @default.
• W1730502540 created "2016-06-24" @default.
• W1730502540 creator A5002450423 @default.
• W1730502540 creator A5036062410 @default.
• W1730502540 creator A5051775018 @default.
• W1730502540 creator A5066757021 @default.
• W1730502540 creator A5069451097 @default.
• W1730502540 creator A5069748055 @default.
• W1730502540 creator A5083177959 @default.
• W1730502540 date "2008-05-20" @default.
• W1730502540 modified "2023-10-14" @default.
• W1730502540 title "Detection of Bcl-2 and apoptosis in circulating tumor cells during treatment of metastatic breast cancer" @default.
• W1730502540 doi "https://doi.org/10.1200/jco.2008.26.15_suppl.11016" @default.
• W1730502540 hasPublicationYear "2008" @default.
• W1730502540 type Work @default.
• W1730502540 sameAs 1730502540 @default.
• W1730502540 citedByCount "2" @default.
• W1730502540 countsByYear W17305025402016 @default.
• W1730502540 countsByYear W17305025402020 @default.
• W1730502540 crossrefType "journal-article" @default.
• W1730502540 hasAuthorship W1730502540A5002450423 @default.
• W1730502540 hasAuthorship W1730502540A5036062410 @default.
• W1730502540 hasAuthorship W1730502540A5051775018 @default.
• W1730502540 hasAuthorship W1730502540A5066757021 @default.
• W1730502540 hasAuthorship W1730502540A5069451097 @default.
• W1730502540 hasAuthorship W1730502540A5069748055 @default.
• W1730502540 hasAuthorship W1730502540A5083177959 @default.
• W1730502540 hasConcept C121608353 @default.
• W1730502540 hasConcept C126322002 @default.
• W1730502540 hasConcept C142724271 @default.
• W1730502540 hasConcept C143998085 @default.
• W1730502540 hasConcept C190283241 @default.
• W1730502540 hasConcept C204232928 @default.
• W1730502540 hasConcept C2775930923 @default.
• W1730502540 hasConcept C2777527632 @default.
• W1730502540 hasConcept C2779012181 @default.
• W1730502540 hasConcept C2779013556 @default.
• W1730502540 hasConcept C502942594 @default.
• W1730502540 hasConcept C530470458 @default.
• W1730502540 hasConcept C55493867 @default.
• W1730502540 hasConcept C61238886 @default.
• W1730502540 hasConcept C71924100 @default.
• W1730502540 hasConcept C74864618 @default.
• W1730502540 hasConcept C86803240 @default.
• W1730502540 hasConceptScore W1730502540C121608353 @default.
• W1730502540 hasConceptScore W1730502540C126322002 @default.
• W1730502540 hasConceptScore W1730502540C142724271 @default.
• W1730502540 hasConceptScore W1730502540C143998085 @default.
• W1730502540 hasConceptScore W1730502540C190283241 @default.
• W1730502540 hasConceptScore W1730502540C204232928 @default.
• W1730502540 hasConceptScore W1730502540C2775930923 @default.
• W1730502540 hasConceptScore W1730502540C2777527632 @default.
• W1730502540 hasConceptScore W1730502540C2779012181 @default.
• W1730502540 hasConceptScore W1730502540C2779013556 @default.
• W1730502540 hasConceptScore W1730502540C502942594 @default.
• W1730502540 hasConceptScore W1730502540C530470458 @default.
• W1730502540 hasConceptScore W1730502540C55493867 @default.
• W1730502540 hasConceptScore W1730502540C61238886 @default.
• W1730502540 hasConceptScore W1730502540C71924100 @default.
• W1730502540 hasConceptScore W1730502540C74864618 @default.
• W1730502540 hasConceptScore W1730502540C86803240 @default.
• W1730502540 hasIssue "15_suppl" @default.
• W1730502540 hasLocation W17305025401 @default.
• W1730502540 hasOpenAccess W1730502540 @default.
• W1730502540 hasPrimaryLocation W17305025401 @default.
• W1730502540 hasRelatedWork W1730502540 @default.
• W1730502540 hasRelatedWork W2154527279 @default.
• W1730502540 hasRelatedWork W2395906155 @default.
• W1730502540 hasRelatedWork W2549802237 @default.
• W1730502540 hasRelatedWork W2590204111 @default.
• W1730502540 hasRelatedWork W2904294837 @default.
• W1730502540 hasRelatedWork W2979892935 @default.
• W1730502540 hasRelatedWork W3033874287 @default.
• W1730502540 hasRelatedWork W4220854896 @default.
• W1730502540 hasRelatedWork W73860091 @default.
• W1730502540 hasVolume "26" @default.
• W1730502540 isParatext "false" @default.
• W1730502540 isRetracted "false" @default.
• W1730502540 magId "1730502540" @default.
• W1730502540 workType "article" @default.